Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

The present disclosure relates to 4-Azaindazole compounds having the following structure: ##STR00001##
or a pharmaceutically acceptable salt thereof, for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

The present disclosure relates to 4-Azaindazole compounds having the following structure: ##STR00001##
or a pharmaceutically acceptable salt thereof, for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

Provided is a compound of Formula (I): ##STR00001## wherein the variable groups are defined herein.

Provided is a compound of Formula (I): ##STR00001## wherein the variable groups are defined herein.

Disclosed herein are embodiments of a Pd(0) precursor complex and embodiments of phosphorus-based Pd(0) catalysts formed therefrom. Also disclosed are method embodiments for making the Pd(0) precursor complex and the phosphorus-based Pd(0) catalysts. The Pd(0) precursor complex can be used to generate, in situ, the phosphorus-based Pd(0) catalysts, in various different types of palladium-mediated coupling reactions.

Disclosed herein are embodiments of a Pd(0) precursor complex and embodiments of phosphorus-based Pd(0) catalysts formed therefrom. Also disclosed are method embodiments for making the Pd(0) precursor complex and the phosphorus-based Pd(0) catalysts. The Pd(0) precursor complex can be used to generate, in situ, the phosphorus-based Pd(0) catalysts, in various different types of palladium-mediated coupling reactions.

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.